Success Metrics

Clinical Success Rate
70.0%

Based on 7 completed trials

Completion Rate
70%(7/10)
Active Trials
20(59%)
Results Posted
114%(8 trials)
Terminated
3(9%)

Phase Distribution

Ph phase_1
16
47%
Ph phase_3
1
3%
Ph phase_2
17
50%

Phase Distribution

16

Early Stage

17

Mid Stage

1

Late Stage

Phase Distribution34 total trials
Phase 1Safety & dosage
16(47.1%)
Phase 2Efficacy & side effects
17(50.0%)
Phase 3Large-scale testing
1(2.9%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

70.0%

7 of 10 finished

Non-Completion Rate

30.0%

3 ended early

Currently Active

20

trials recruiting

Total Trials

34

all time

Status Distribution
Active(24)
Completed(7)
Terminated(3)

Detailed Status

Recruiting12
Active, not recruiting8
Completed7
Not yet recruiting4
Terminated3

Development Timeline

Analytics

Development Status

Total Trials
34
Active
20
Success Rate
70.0%
Most Advanced
Phase 3

Trials by Phase

Phase 116 (47.1%)
Phase 217 (50.0%)
Phase 31 (2.9%)

Trials by Status

not_yet_recruiting412%
completed721%
terminated39%
active_not_recruiting824%
recruiting1235%

Recent Activity

Clinical Trials (34)

Showing 20 of 34 trialsScroll for more
NCT05417594Phase 1

Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies

Recruiting
NCT07562971Phase 1

Focused Ultrasound Blood-Brain Barrier Opening in Pontine Diffuse Midline Glioma to Enhance Temozolomide Therapy: Pilot Feasibility Study (FIDES)

Not Yet Recruiting
NCT07326566Phase 2

Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII

Recruiting
NCT05843253Phase 2

Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant

Recruiting
NCT07243470Phase 1

Combination of Tarlatamab and Temozolomide in Patients With Central Nervous System Tumors

Recruiting
NCT06721689Phase 1

PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors

Recruiting
NCT03749187Phase 1

BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas

Active Not Recruiting
NCT04457284Phase 2

Temozolomide, Cisplatin, and Nivolumab in People With Colorectal Cancer

Active Not Recruiting
NCT06478212Phase 1

Vorasidenib in Combination With Temozolomide (TMZ) in IDH-mutant Glioma

Active Not Recruiting
NCT02942264Phase 1

Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma

Terminated
NCT01356290Phase 2

Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors

Recruiting
NCT03405792Phase 2

Study Testing The Safety and Efficacy of Adjuvant Temozolomide Plus TTFields (Optune®) Plus Pembrolizumab in Patients With Newly Diagnosed Glioblastoma (2-THE-TOP)

Active Not Recruiting
NCT07389278Phase 1

Combination ADI-PEG 20, TMZ, and RT for Treatment of Newly Diagnosed High-grade Glioma (HGG)

Not Yet Recruiting
NCT06208657Phase 1

Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer

Recruiting
NCT07365280Phase 2

Neoantigen-Pulsed Autologous Dendritic Cell Vaccine Combined With Temozolomide for Newly Diagnosed Glioblastoma

Not Yet Recruiting
NCT04752813Phase 2

A Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB)

Active Not Recruiting
NCT07346157Phase 1

Liothyronine in Combination With BIT Regimen for Medulloblastoma With or Without Minimal Residual Disease

Not Yet Recruiting
NCT07334301Phase 1

A Multi-Arm, Platform Trial For Relapsed Neuroblastoma

Recruiting
NCT03212742Phase 1

Phase I/IIa Study of Concomitant Radiotherapy With Olaparib and Temozolomide in Unresectable High Grade Gliomas Patients

Active Not Recruiting
NCT03535350Phase 1

Ibrutinib With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma

Active Not Recruiting

Drug Details

Intervention Type
DRUG
Total Trials
34